SLDB Solid Biosciences Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

SLDB [NASD]

Solid Biosciences Inc.

Healthcare | Drug Manufacturers - Specialty & Generic | USA

statements

Index	-	P/E	-	EPS (ttm)	-2.29	Insider Own	4.80%	Shs Outstand	48.16M	Perf Week	0.40%
Market Cap	158.10M	Forward P/E	-	EPS next Y	-0.78	Insider Trans	-1.37%	Shs Float	28.31M	Perf Month	87.87%
Income	-106.80M	PEG	-	EPS next Q	-0.35	Inst Own	58.60%	Short Float	4.91%	Perf Quarter	48.82%
Sales	-	P/S	-	EPS this Y	-29.40%	Inst Trans	0.36%	Short Ratio	0.37	Perf Half Y	50.00%
Book/sh	0.85	P/B	4.46	EPS next Y	45.80%	ROA	-116.60%	Target Price	4.70	Perf Year	-69.71%
Cash/sh	0.97	P/C	3.91	EPS next 5Y	-	ROE	-149.50%	52W Range	1.93 - 13.58	Perf YTD	-14.72%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-72.05%	Beta	-
Dividend %	-	Quick Ratio	3.30	Sales past 5Y	-	Gross Margin	-	52W Low	96.63%	ATR	0.40
Employees	121	Current Ratio	3.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	59.13	Volatility	8.09% 12.54%
Optionable	Yes	Debt/Eq	0.02	EPS Q/Q	48.20%	Profit Margin	-	Rel Volume	3.59	Prev Close	3.43
Shortable	Yes	LT Debt/Eq	0.01	Earnings	-	Payout	-	Avg Volume	3.73M	Price	3.80
Recom	3.30	SMA20	7.71%	SMA50	33.06%	SMA200	30.24%	Volume	13,365,208	Change	10.64%

Jul-28-20

Downgrade

SVB Leerink

Outperform → Mkt Perform

May-07-20

Downgrade

Evercore ISI

Outperform → In-line

Oct-11-19

Initiated

Evercore ISI

Outperform

$22

Aug-29-19

Downgrade

Citigroup

Neutral → Sell

Aug-19-19

Upgrade

SVB Leerink

Mkt Perform → Outperform

$8 → $15

Aug-16-19

Upgrade

Chardan Capital Markets

Neutral → Buy

$7.50 → $10

May-14-19

Downgrade

Goldman

Neutral → Sell

$5 → $4

May-14-19

Downgrade

Credit Suisse

Neutral → Underperform

$7 → $6

Feb-08-19

Upgrade

Citigroup

Sell → Neutral

Feb-08-19

Downgrade

SVB Leerink

Outperform → Mkt Perform

Nov-06-18

Initiated

Citigroup

Sell

Sep-06-18

Initiated

Credit Suisse

Neutral

$38

Oct-23-20 08:00AM	Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy GlobeNewswire +10.64%
Oct-09-20 08:54AM	Do Options Traders Know Something About Solid Biosciences (SLDB) Stock We Don't? Zacks
Oct-02-20 02:56PM	Solid Biosciences (SLDB) Stock Will Surge Over 200% From Current Levels, Says Analyst TipRanks +20.81%
07:30AM	Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 4th Annual Genetic Medicines Conference GlobeNewswire
Oct-01-20 02:56PM	Why Solid Biosciences Stock Has Doubled Today Barrons.com +70.44%
11:02AM	Why Solid Biosciences Stock Is Trading Higher Today Benzinga
07:30AM	Solid Biosciences Announces FDA Lifts Clinical Hold on IGNITE DMD Clinical Trial GlobeNewswire
Sep-11-20 02:45PM	SOLID BIOSCIENCES (SLDB) INVESTOR ALERT: Lawsuit Investigation ACCESSWIRE
Sep-10-20 10:19AM	FDA Delays Start of Sareptas Gene Therapy Trial. That Doesnt Faze the Stocks Bulls. Barrons.com
Aug-21-20 03:00PM	SOLID BIOSCIENCES (SLDB) INVESTOR ALERT: Lawsuit Investigation ACCESSWIRE
Jul-29-20 09:12PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Solid Biosciences Inc. - SLDB PR Newswire
Jul-28-20 12:50PM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Solid Biosciences Inc. (SLDB) Investigation ACCESSWIRE -6.27%
Jul-27-20 12:16PM	FDA Again Keeps Solid Biosciences Duchenne Trial On Clinical Hold TipRanks -10.53%
Jul-24-20 05:50PM	Solid Biosciences Provides Update Regarding the IGNITE DMD Phase I/II Clinical Hold GlobeNewswire
Jul-05-20 05:27PM	Solid Biosciences Inc. (SLDB): Hedge Fund Sentiment Unchanged Insider Monkey
Jun-18-20 07:00AM	Solid Biosciences Announces Appointment of Ian F. Smith as Chairman of the Board of Directors GlobeNewswire
Jun-12-20 06:45AM	Solid Biosciences (NASDAQ:SLDB) Will Have To Spend Its Cash Wisely Simply Wall St.
May-29-20 08:35AM	Why Solid Biosciences (SLDB) Stock Might be a Great Pick Zacks
May-22-20 07:00AM	Solid Biosciences to Hold Virtual Annual Meeting of Stockholders on June 16, 2020 GlobeNewswire
May-14-20 07:00AM	Solid Biosciences Presents Data from Duchenne Muscular Dystrophy Gene Therapy Program at ASGCT 23rd Annual Meeting GlobeNewswire
May-13-20 09:49AM	Top Ranked Momentum Stocks to Buy for May 13th Zacks
May-11-20 03:03AM	Solid Biosciences: Keep Your Eyes On The Prize Says Top Analyst SmarterAnalyst
May-09-20 01:48PM	Chardan Capital Sticks to Their Buy Rating for Solid Biosciences Llc Investing.com
May-07-20 07:22AM	Solid Biosciences Provides Update regarding SGT-001 Phase I/II Clinical Hold on IGNITE DMD GlobeNewswire -14.34%
Apr-16-20 07:00AM	Solid Biosciences Announces Appointment of Ian F. Smith to its Board of Directors GlobeNewswire
Mar-12-20 07:00AM	Solid Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update GlobeNewswire -7.01%
Jan-31-20 05:00AM	Families of rare-disease patients take on drug development, but face uphill battle American City Business Journals
Jan-22-20 11:48AM	New FDA documents shed light on agency's rejection of Sarepta drug American City Business Journals
Jan-10-20 10:08AM	Applied Genetic Stock Up on Favorable Eye Therapy Study Data Zacks -5.15%
Jan-09-20 08:00AM	Solid Biosciences Announces Organizational Changes to Prioritize Development of SGT-001 GlobeNewswire -14.45%
Dec-23-19 10:11AM	Sarepta Signs Gene Therapy Agreement With Roche for $1.15B Zacks
Dec-19-19 06:08PM	Is Solid Biosciences Inc. (SLDB) Going to Burn These Hedge Funds? Insider Monkey
Dec-18-19 08:46AM	Benzinga Pro's Top 5 Stocks To Watch For Wed., Dec. 18, 2019: UPS, MU, EPZM, SLDB, XXII Benzinga -17.40%
08:38AM	Solid Biosciences stock are up on DMD study news MarketWatch
06:30AM	Solid Biosciences Provides Data Update from SGT-001 Development Program GlobeNewswire
Dec-16-19 08:52AM	Options Traders Expect Huge Moves in Solid Biosciences (SLDB) Stock Zacks +8.15%
Dec-13-19 08:55AM	Sarepta's Vyondys 53 Receives FDA Approval for DMD, Stock Up Zacks
Nov-20-19 01:28PM	Hedge Fund Innovator Joseph Edelman Doubles Down on These 3 Biotech Stocks TipRanks
Nov-13-19 03:43PM	Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates Zacks +8.51%
Nov-12-19 05:51PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Solid Biosciences Inc. - SLDB GlobeNewswire -74.36%
04:03PM	Biotech Pops After Rival's Gene Therapy Halted By Regulators Investor's Business Daily
10:56AM	FDA intervenes for 3rd time in Solid Biosciences' Duchenne drug tests American City Business Journals
10:22AM	Solid Biosciences Shares Crash To Record Low After FDA Places Gene Therapy Program On Hold Benzinga
10:15AM	Solid Biosciences Stock Crashes Over Safety Concerns About Its Gene Therapy Barrons.com
07:00AM	Solid Biosciences gene therapy trial put on hold by FDA Reuters
06:45AM	Solid Biosciences Provides SGT-001 Program Update GlobeNewswire
Oct-16-19 08:42AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Solid Biosciences Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire +10.70%
Oct-02-19 07:30AM	Solid Biosciences to Participate in the Chardan 3rd Annual Genetic Medicines Conference GlobeNewswire
Sep-03-19 02:21PM	In expense-laden biotech industry, here are the Mass. startups most in need of cash American City Business Journals
Aug-29-19 11:38AM	Citi: Solid Biosciences Rally Unsupported By Fundamentals Benzinga -7.37%
09:02AM	Sell Solid Biosciences Stock Because Its Muscular Distrophy Drug Is Unlikely to Be Competitive Barrons.com
Aug-27-19 07:23AM	Will Solid Biosciences Continue to Surge Higher? Zacks
Aug-20-19 12:20PM	Sarepta's FDA rejection could have ripple effect in other Duchenne biotechs American City Business Journals
12:02PM	Parents Push One Rare-Disease Drug Through FDA, Not Its Successor Bloomberg
10:03AM	Sarepta Stock Falls as FDA Denies Approval to Golodirsen Zacks
Aug-19-19 03:17PM	Solid Biosciences Stock Surge Ignites Options Activity Schaeffer's Investment Research +5.56%
08:58AM	Solid Biosciences Surges on DMD Gene Therapy Study Amendments Zacks
Aug-16-19 12:15PM	Here's Why Solid Biosciences Is Soaring Today Motley Fool +43.25%
Aug-15-19 02:41PM	Sarepta's Lone Analyst Skeptic Takes On 22 Bulls With Renewed Warnings Bloomberg
Aug-14-19 07:25AM	Solid Biosciences Reports Second Quarter 2019 Financial Results and Provides Business Update GlobeNewswire +23.79%
Aug-08-19 10:33AM	Sarepta (SRPT) Q2 Loss Widens Y/Y, Golodirsen Nears Approval Zacks +7.50%
Jul-26-19 07:25AM	Solid Biosciences Announces $60 Million Private Placement with New and Existing Investors GlobeNewswire +34.41%
Jul-01-19 09:35AM	Sarepta Up as Pfizer's DMD Gene Therapy Faces Safety Issues Zacks -9.04%
09:21AM	Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study Zacks
Jun-28-19 06:51PM	Heres What Hedge Funds Think About Solid Biosciences Inc. (SLDB) Insider Monkey +13.86%
04:28PM	Gene Therapy Battle: Pfizer's Test Results Sent This Biotech Stock Flying Investor's Business Daily
Jun-12-19 04:04PM	Bain's second life sciences fund comes in over $1 billion American City Business Journals +5.25%
Jun-06-19 06:10PM	Vertex enters Duchenne field with $245M buy of Exonics American City Business Journals
May-16-19 03:00PM	Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Solid Biosciences Inc. (SLDB) GlobeNewswire
10:00AM	Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Solid Biosciences Inc. (SLDB) ACCESSWIRE
May-14-19 04:27PM	This Biotech Is More Than Its Lead Gene Therapies: Here Are 4 Drugs To Note Investor's Business Daily -28.59%
01:56PM	Solid Bios Plunge Sends a Warning on Gene Therapies Bloomberg
12:26PM	Here's Why Solid Biosciences Fell as Much as 40.9% Today Motley Fool
11:51AM	Solid Biosciences Tanks After Reporting Adverse Event In Duchenne Muscular Dystrophy Trial Benzinga
07:42AM	The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings Benzinga
May-13-19 04:10PM	Solid Biosciences Reports First Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
May-03-19 10:13AM	Heres What Hedge Funds Think About About Solid Biosciences Inc. (SLDB) Insider Monkey
Apr-17-19 11:10AM	Wave Life Sciences Plunges After DMD Study Data Readout Zacks
Apr-16-19 02:39PM	Bain Capital raising another life sciences fund after $720M debut American City Business Journals
Apr-15-19 04:01PM	Solid Biosciences Announces Upcoming Preclinical Data Presentations at The American Society of Gene and Cell Therapy Annual Meeting GlobeNewswire
Apr-08-19 09:45AM	4 Gene Therapy Players Likely to Become Buyout Targets in 2019 Zacks
Mar-28-19 10:20AM	Sarepta plans second Duchenne drug application this year American City Business Journals
Mar-13-19 07:30AM	Solid Biosciences Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update GlobeNewswire
Mar-10-19 10:36AM	10 Stocks For The Gene Therapy Revolution Investopedia
Feb-27-19 09:53AM	The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure Zacks
Feb-26-19 11:15AM	Biotech ETFs Jump on Roche-Spark Deal Zacks
08:54AM	5 Gene Therapy Stocks to Enrich Your Portfolio Zacks
Feb-25-19 03:12PM	Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal Benzinga +9.60%
Feb-20-19 03:52PM	Lifshitz & Miller LLP Announces Investigation of Bristow Group Inc., Helius Medical Technologies, Inc., Nordstrom Inc., PriceSmart, Inc., Ryanair Holdings plc, Solid Biosciences Inc., and Vanda Pharmaceuticals Inc. PR Newswire +6.34%
Feb-15-19 08:56AM	Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review Zacks
Feb-07-19 08:37PM	What Solid Biosciences' First Failure Means for Sarepta Therapeutics Motley Fool -67.82%
04:11PM	Why This Biotech Stock Cratered 68% On Its Gene Therapy Study Investor's Business Daily
01:47PM	A Setback for Solid Is a Win for Sarepta in Race to Treat Muscular Dystrophy Barrons.com
11:22AM	SHAREHOLDER ALERT: Investigation of Solid Biosciences Inc. Announced by Holzer & Holzer, LLC Business Wire
11:05AM	Here's Why Solid Biosciences Plunged Today Motley Fool
10:45AM	Solid Biosciences shares drop 70% on disappointing Duchenne data American City Business Journals
09:42AM	Solid Bio Crashes on Gene Therapy Data as Peer Sarepta Gains Bloomberg
09:25AM	Solid Biosciences stock falls 73% after preliminary Phase 1/2 trial shows efficacy issues with drug MarketWatch
06:45AM	Solid Biosciences Announces Preliminary SGT-001 Data and Intention to Dose Escalate in IGNITE DMD Clinical Trial for Duchenne Muscular Dystrophy GlobeNewswire
Jan-02-19 08:00AM	Solid Biosciences to Present at the J.P. Morgan Healthcare Conference GlobeNewswire +7.91%

Solid Biosciences Inc., a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a monoclonal antibody that is in preclinical trials to reduce fibrosis and inflammation. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits to DMD patients. Solid Biosciences Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ganot Ilan	CEO & President	Aug 13	Sale	2.44	299	730	3,483	Aug 14 04:07 PM
Schneider Joel Solomon Zev	Chief Technology Officer	Jul 28	Sale	2.42	4,041	9,776	284,115	Jul 29 07:26 PM
Morris Carl Ashley	Chief Scientific Officer	Jul 28	Sale	2.42	3,591	8,689	290,959	Jul 29 05:37 PM
Ziolkowski Jennifer Lynn	CFO, Treasurer & Asst. Secy	Jul 28	Sale	2.42	3,591	8,687	327,609	Jul 29 05:33 PM
HERSCHA LYNETTE	Chief Legal Officer	Jul 28	Sale	2.42	5,141	12,438	160,859	Jul 29 05:28 PM
Ganot Ilan	CEO & President	Jul 28	Sale	2.42	11,124	26,910	1,148,007	Jul 29 05:23 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience